Racura Oncology Advances RC220 to New Dose Level in Lung Cancer Trial
Racura Oncology received safety review committee clearance to advance lead candidate RC220 in its Phase 1 Harness-1 trial (RAC-020). The trial evaluates the drug with standard-of-care tyrosine kinase inhibitor osi…